Early clinical studies report promising seizure reductions for children with Dravet syndrome. Zorevunersen has shown sustained improvements in seizure frequency, quality of life, and adaptive behavior, supporting its continued development as a potential disease-modifying therapy.
Dravet syndrome, a rare and severe form of epilepsy, is typically caused by genetic mutations affecting sodium channel function. Children with this condition face frequent seizures, developmental delays, and increased risks of sudden unexpected death in epilepsy. Existing treatments often involve combinations of antiseizure medications, but many patients still experience significant seizure burden and progressive neurodevelopmental issues.
Two Phase 1 to 2a open-label trials, MONARCH and ADMIRAL, assessed zorevunersen in 81 patients aged 2 to 18 years with Dravet syndrome already on standard therapies. Most adverse events were mild to moderate. In patients receiving doses up to 45 mg, median convulsive seizure frequency decreased by 58.82% to 90.91% within the first 20 months, with consistent reductions observed over time.
These emerging results suggest zorevunersen could address the underlying genetic deficiency in Dravet syndrome. Larger, controlled trials are needed to confirm efficacy, long-term safety, and its integration into standard pediatric neurology practices.